

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

BAYER AG, BAYER HEALTHCARE)
AG, and BAYER PHARMACEUTICALS)
CORPORATION,)
)
Plaintiffs,)
)
v.) Civ. No. 04-179-SLR
)
DR. REDDY'S LABORATORIES, LTD.,)
and DR. REDDY'S LABORATORIES,)
INC.,)
)
Defendants.)

DR. REDDY'S LABORATORIES, LTD.,)
and DR. REDDY'S LABORATORIES,)
INC.,)
)
Counterclaim Plaintiffs,)
)
v.)
)
BAYER AG, BAYER HEALTHCARE)
AG, and BAYER PHARMACEUTICALS)
CORPORATION,)
)
Counterclaim Defendants.)

ORDER


At Wilmington this ~~25th~~ day of October, 2007, consistent with the opinion issued
this same date;

IT IS ORDERED that:

1. The effective date of any approval of Reddy's ANDA will be no earlier than
March 4, 2014.

2. Reddy shall not manufacture, use, offer for sale, or sell within the United States, or import into the United States, moxifloxacin hydrochloride or any compound or drug product within the scope of claim 1 or 2 of the '942 patent, prior to March 5, 2014.

3. On or before November 23, 2007, the parties shall submit a joint proposed order of judgment for the court's signature.


United States District Judge